CCR4 and T-cell non-Hodgkin lymphoma: The other two defucosylated mAbs approved for clinical application are mogamulizumab, an anti-CCR4 antibody used for T cell lymphoma [43], and benralizumab, an anti-IL-5R antibody used for severe eosinophilic asthma [44].